Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
about
A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-AnalysisPredictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-AnalysisCommon variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patientsERCC1 and XRCC1 as biomarkers for lung and head and neck cancerTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerA haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study.Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancerAssociation between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Basic principles and technologies for deciphering the genetic map of cancer.Epidemiology of lung cancer prognosis: quantity and quality of life.Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patientsMeta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.ERCC1 and personalized medicine in lung cancerVariants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx.No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes.The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivityPredictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Predictive role of XRCC5/XRCC6 genotypes in digestive system cancers.Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancerGlutathione S-Transferase Gene Polymorphisms and Treatment Outcome in Cervical Cancer Patients under Concomitant Chemoradiation.Pharmacogenomics of platinum-based chemotherapy in NSCLCSarcomas and pharmacogenetics.Pharmacogenetics of colorectal cancer.Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer managementClinical implications of genetic polymorphisms on stomach cancer drug therapy.XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients.Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han populationTesting for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
P2860
Q26750858-09F6D852-786A-4CD7-B254-95F444A5E354Q26782962-5371AED5-4300-4166-9170-5A008065E7E5Q27851470-98C553A1-DE8D-4768-A836-E086D290CADFQ27851471-4C667EC9-75CF-4491-A742-9570270C2165Q28382908-0266CCD3-9CAF-4DC1-A0B5-1A8DB9F3F7F6Q28391646-1B77B980-8C13-4EE7-9DE7-D078AC8B1799Q28396304-424A032B-A5A6-460B-991E-DC50A41D460AQ33320697-BE81BA4B-F6CA-4A0F-860E-6B7D6CCE25A5Q33391561-9E5433C6-12C1-4EC8-85D4-C60FD65F697EQ33406047-1C07B4A9-1DFB-4AEB-9061-534BA74B5DEDQ33518016-0D3740F0-3859-484E-983F-A87957441463Q33793009-9E4C711B-0DA3-46FD-9FFE-1078E8C51733Q33912148-A246B2DC-3EEC-452B-A180-B42E5AE6D9A8Q34074628-51762FA3-38C5-4A64-979E-72A286BFCE6CQ34135295-79F769C2-8C88-44D5-9582-73CF0F0828E2Q34160556-9EBD8E9E-F71C-4840-BAB0-A2AFE593D95DQ34325669-121FD1EF-3B15-4D5F-8286-56C20C7F377BQ34357698-898EE9C0-5AD9-45E8-8FEF-813F01E92558Q34555379-ADF284A2-E84C-4A6C-B2BA-C0D660BE978CQ34630819-C0D7B4C3-88C9-4AF4-BC41-0C7B7E424BBAQ34672604-A2EB1797-5B94-4AA0-B6B0-88E864527B3CQ34676948-F0DFD276-6DE5-4293-B573-7358BDB442A0Q34686858-403AF8A6-15A2-44DD-A9E1-6A2E7A26178DQ34973738-199531C5-9699-4293-A0EC-A5A6932E8D39Q35048754-9E5E185F-BEF8-4856-A3EF-139B669EC4F0Q35072797-8BBA1319-50A4-4D27-BCEA-743347EEF1B4Q35584647-FCD2C4FC-A063-4362-AB84-F00CC4C877ADQ35653296-36AD5DFE-3096-4F27-924B-7597CE7D5D92Q35730375-E2723D8E-F72B-4B46-B977-0B6AFC92C0B8Q35842082-7BE1EDA5-DDB4-486B-9BE6-FCFFF1903C9DQ36158678-63F80A46-FEE5-4C6F-BE71-13C6745B88DEQ36249224-C66A47A9-8DF6-4BF3-8F87-707F17DB8574Q36326214-14702FB5-B840-427B-9767-A076F7FE0EDBQ36375374-3E72C8E5-ACA0-417A-A113-62B904F29969Q36441485-8F502811-9DD8-472B-9C5D-3DCC550538A6Q36519876-8DC7331F-D0C5-4966-9B92-57F5BF0AA42EQ36538494-8D1C372C-BCCA-47B5-B220-355B3E9EE73EQ36612270-EA32683F-0805-439B-B84B-8FEBA54365F9Q36681506-16187AC9-E3BF-41D9-90AD-400480A377A3Q36816030-2510F4F5-78F8-4D93-A75A-E54F3CE52C0A
P2860
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Association between polymorphi ...... atin combination chemotherapy.
@en
Association between polymorphi ...... atin combination chemotherapy.
@nl
type
label
Association between polymorphi ...... atin combination chemotherapy.
@en
Association between polymorphi ...... atin combination chemotherapy.
@nl
prefLabel
Association between polymorphi ...... atin combination chemotherapy.
@en
Association between polymorphi ...... atin combination chemotherapy.
@nl
P2093
P1433
P1476
Association between polymorphi ...... atin combination chemotherapy.
@en
P2093
Hye-Seung Han
Jeong-Seon Ryu
Jong-Eun Lee
Tae-Sook Hwang
Young-Chul Kim
Young-Mee Park
Yun-Chul Hong
P304
P356
10.1016/J.LUNGCAN.2003.11.019
P577
2004-06-01T00:00:00Z